Otospiralin Activators
Otospiralin Activators encompass a diversearray of chemical compounds that indirectly boost the activity of Otospiralin by targeting signaling pathways with which it may be associated. Otospiralin, a protein known for its role in the inner ear, particularly in cochlear hair cells, is thought to contribute to the structural stability necessary for proper auditory function. Forskolin, by increasing intracellular cAMP, indirectly promotes Otospiralin function through protein kinase A (PKA), which is known to phosphorylate various proteins that could be involved in the same cellular processes as Otospiralin, thereby potentially enhancing its stabilizing role in the cochlea. Similarly, Rolipram and Cilostazol elevate cAMP levels via phosphodiesterase inhibition, promoting Otospiralin activity via PKA signaling, which could affect the protein's involvement in cochlear cell stability. Isoproterenol, a beta-adrenergic agonist, and IBMX, a non-selective phosphodiesterase inhibitor, also raise cAMP levels, further potentiating Otospiralin's function through PKA-dependent pathways. Moreover, ANP and compounds like BAY 41-2272 and Vardenafil, which elevate cGMP levels, could activate Otospiralin through cGMP-dependent protein kinase (PKG) pathways, influencing inner ear fluid homeostasis and auditory mechanics.
The pharmacological actions of these activators highlight the intricate interplay between Otospiralin and cellular signaling mechanisms. Sildenafil and Vardenafil, as specific phosphodiesterase type 5 inhibitors, increase cGMP levels, potentially supporting Otospiralin's role in the inner ear through PKG pathways. Vinpocetine, by inhibiting phosphodiesterase 1, raises both cAMP and cGMP levels, which might allow for dual enhancement of Otospiralin's activity through PKA and PKG, respectively, fostering cochlear cell function. Zaprinast's inhibition of phosphodiesterases 5 and 6 similarly suggests a mechanism for elevating cGMP and enhancing Otospiralin function through PKG pathways. Lastly, Milrinone, as a phosphodiesterase 3 inhibitor, boosts cAMP and thus could indirectly augment Otospiralin activity through PKA signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, leading to an increase in cAMP levels. Elevated cAMP activates PKA, which may phosphorylate proteins involved in the cellular pathways where Otospiralin is active, thereby enhancing Otospiralin’s stabilization role in cochlear hair cells and potentially supporting hearing function. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase 4, preventing the breakdown of cAMP. This raises intracellular cAMP levels, indirectly enhancing Otospiralin activity by similar mechanisms as Forskolin, through PKA-mediated pathways. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Cilostazol increases cAMP levels by inhibiting phosphodiesterase 3. This could enhance Otospiralin activity by activating PKA, which may influence pathways that stabilize the structure and function of cochlear cells. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine inhibits phosphodiesterase 1, leading to increased cAMP and cGMP levels. This dual effect could enhance Otospiralin activity via the activation of PKA and PKG, promoting cochlear cell function and auditory processes. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a beta-adrenergic agonist, increases cAMP levels through the activation of adenylyl cyclase, which may enhance Otospiralin activity via PKA-dependent signaling pathways, contributing to the protein's role in cochlear mechanics. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, increasing levels of cAMP and cGMP. This promotes Otospiralin activity through PKA and PKG pathways, potentially affecting its role in the cochlea. | ||||||
BAY 41-2272 | 256376-24-6 | sc-202491 sc-202491A | 5 mg 25 mg | $238.00 $728.00 | 4 | |
BAY 41-2272 activates soluble guanylyl cyclase, leading to increased cGMP levels. The subsequent activation of PKG pathways could enhance Otospiralin activity, potentially stabilizing cochlear function and aiding in hearing. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Vardenafil, a PDE5 inhibitor, raises cGMP levels, which could enhance Otospiralin activity through PKG-mediated signaling, potentially influencing the mechanics and stability of cochlear hair cells. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterase 5 and 6, increasing cGMP levels. This could support Otospiralin activity by enhancing PKG-dependent pathways, which may be involved in the function of cochlear cells. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone is a phosphodiesterase 3 inhibitor that increases cAMP levels. By enhancing PKA signaling, it may indirectly elevate Otospiralin activity, supporting its role in maintaining cochlear cell structure and auditory functions. | ||||||